Animal Studies on Nano-PSO (GranaGard®) and Multiple Sclerosis
In animal studies, Nano-PSO treatment showed potential benefits, like improved verbal learning in a small preliminary study on Multiple Sclerosis (MS). However, these findings highlight the need for further research, including larger, controlled studies to confirm the results.
- Tags
- #MSResearch
- Most relevant to
- —
- Human efficacy
- Not yet tested in people
- Mechanism
- Not reported
- Evidence strength
- Early – laboratory or animal research
- Outcome
- Not reported
Results in cells or animals often do not carry over to people with MS.
Why it matters
This research suggests Nano-PSO could be a promising therapeutic approach for MS by enhancing bioavailability of important compounds associated with neuroprotection.
What this does not prove
The findings are preliminary, lacking large-scale verification and do not establish definitive clinical relevance or human efficacy.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Not reported
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-10-21
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
- Biological target
- punicic acid (PA), neuroprotective conjugated linoleic acid (CLA)
- Pathway
- Not reported
- Population
- Not reported
- Size of effect
- Not reported
- Secondary endpoints
- Not reported
- MRI endpoints
- Not reported
- Biomarkers
- Not reported
- Safety
- Not reported
Original sources
- Primary evidenceEfficacy of Pomegranate Seed Oil (PSO) in Its Nanoformulation (GranaGard®) in Neurodegenerative Disease Modulation. ↗DOI: 10.3390/cimb48101087
Supporting passages (8)
peer reviewedPublication types: Journal Article; Review
publication datePublication date: 2026-10-21
interventionTo address these limitations, GranaGard® (Nano-PSO), a self-emulsifying nanoformulation, was developed to improve the bioavailability and CNS delivery of PSO-derived compounds.
findingsIn a small preliminary clinical study in Multiple Sclerosis (MS), Nano-PSO treatment was associated with improved verbal learning in a within-group analysis, although large controlled studies are needed.
limitationsThese preliminary findings warrant further investigation, including independent replication and controlled clinical studies to establish the reproducibility and clinical relevance of Nano-PSO.
biological targetsNano-PSO significantly increases systemic absorption and brain accumulation of its bioactive metabolite, neuroprotective conjugated linoleic acid (CLA).
subjectsIn a transgenic mouse model of Creutzfeldt-Jakob Disease (CJD), continuous Nano-PSO administration was reported to delayed disease onset, prolong survival, reduce lipid oxidation, preserve neuronal viability, and increase neurogenesis.
human efficacyIn a transgenic mouse model of Creutzfeldt-Jakob Disease (CJD), continuous Nano-PSO administration was reported to delayed disease onset, prolong survival, reduce lipid oxidation, preserve neuronal viability, and increase neurogenesis.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.